Insider Trading July 6, 2026 07:36 PM

Sight Sciences COO Alison Bauerlein Sells $129,626 in Stock

Insider transaction reflects RSU vesting; mixed Q1 earnings underscore valuation and volatility concerns

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
SGHT

Alison Bauerlein, Chief Operating Officer of Sight Sciences, Inc. (NASDAQ: SGHT), executed a sale of 24,184 shares on July 2, 2026, generating approximately $129,626 in proceeds. The transaction was structured to cover tax liabilities tied to the vesting of restricted stock units. Following the sale, Bauerlein retains direct ownership of 664,709 shares, comprising both vested common stock and unvested RSUs. The company’s recent Q1 2026 financial results present a mixed picture, with revenue beating estimates but earnings per share falling short. Market analysis suggests the stock may be overvalued, and its high beta indicates significant price volatility relative to broader market movements.

Sight Sciences COO Alison Bauerlein Sells $129,626 in Stock
SGHT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Alison Bauerlein sold 24,184 shares to cover tax liabilities from RSU vesting, retaining 664,709 shares post-transaction.
  • Q1 2026 revenue of $19.7 million beat estimates by 6.2%, but EPS of -$0.24 missed forecasts by 41.18%.
  • Stock shows 30% annual gain but faces overvaluation concerns and high volatility with a beta of 2.38.

Alison Bauerlein, who serves as Chief Operating Officer at Sight Sciences, Inc. (NASDAQ: SGHT), completed a transaction on July 2, 2026, selling 24,184 shares of the company’s common stock. The aggregate value of this sale reached approximately $129,626. The shares were liquidated at a weighted average price of $5.36 per share, with individual transaction prices ranging from $5.19 to $5.46. Sight Sciences states that the sale was executed specifically to cover tax liabilities associated with the vesting of restricted stock units. Following this transaction, Ms. Bauerlein directly holds 664,709 shares. This total includes 192,669 shares of common stock and 472,040 shares that represent unvested restricted stock units.

The stock currently trades at $5.48, reflecting a 30% gain over the past year. Despite this appreciation, InvestingPro analysis indicates that the company appears overvalued at current levels. The stock exhibits a beta of 2.38, signaling significant volatility relative to the broader market. Investors monitoring Sight Sciences may find the revenue growth encouraging, though the earnings per share miss highlights areas for potential improvement. These developments are crucial for stakeholders and analysts observing the company’s performance.

In other recent news, Sight Sciences reported its Q1 2026 earnings, showing a mixed financial performance. The company achieved a revenue of $19.7 million, surpassing expectations by 6.2%. However, Sight Sciences reported an earnings per share of -$0.24, which was below the forecast by 41.18%. Despite the mixed results, the stock price remained relatively stable following the announcement. Investors may find the revenue growth encouraging, though the EPS miss highlights areas for potential improvement. These recent developments are crucial for stakeholders and analysts observing the company’s performance.

Risks

  • Overvaluation concerns suggest potential downside risk for investors at current price levels.
  • High beta of 2.38 indicates significant price volatility relative to broader market movements.
  • Mixed earnings results highlight potential improvement areas in profitability and operational efficiency.

More from Insider Trading

Aura Minerals COO Rosa Glauber Executes $1.24 Million Share Sale Under Pre-Arranged Plan Jul 6, 2026 SentinelOne Executive Share Sale Clarified as Tax Withholding Mechanism Jul 6, 2026 SentinelOne Executive Completes Mandatory Stock Sale to Cover Tax Obligations Jul 6, 2026 Natera President Solomon Moshkevich Offloads $818K in Shares Amid Stock Surge Jul 6, 2026 Natera Executive Daniel Rabinowitz Executes $4.57M Stock Sale Under Pre-Arranged Plan Jul 6, 2026